Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,778 SEK | +0,11% | -2,31% | -55,66% |
01/03 | Aandelen Sana Biotechnology stijgen na kleiner niet-GAAP nettoverlies in Q4 | MT |
01/03 | Sectorupdate: Gezondheidszorgaandelen randen hoger premarket vrijdag | MT |
Vakgebied
Aantal werknemers: 23
Verkoop per activiteit
SEK in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100,0
%
| 10 | 100,0 % | 15 | 100,0 % | +45,86% |
Verkoop per regio
SEK in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Other European Countries
75,4
%
| 8 | 76,1 % | 12 | 75,4 % | +44,49% |
Americas
24,6
%
| 3 | 23,9 % | 4 | 24,6 % | +50,16% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 66 | 01-01-11 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 01-01-11 |
Jørgen Drejer
FOU | Founder | 69 | 01-01-11 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 01-01-14 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 01-05-20 | |
Corporate Officer/Principal | 52 | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 01-01-11 |
Director/Board Member | 66 | 01-01-15 | |
Anna Ljung
BRD | Director/Board Member | 44 | 19-01-18 |
Director/Board Member | 58 | 01-01-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 132 529 086 | 92 446 630 ( 69,76 %) | 0 | 69,76 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Sector
Verkoop per regio
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-55,66% | 18,25 mln. | |
-1,51% | 105 mld. | |
+3,22% | 97,5 mld. | |
+1,86% | 22,19 mld. | |
-16,53% | 21,33 mld. | |
-8,49% | 18,68 mld. | |
-42,33% | 16,6 mld. | |
-20,09% | 14,52 mld. | |
+5,47% | 14,09 mld. | |
+28,85% | 10,99 mld. |
- Beurs
- Aandelen
- Koers SANION
- Onderneming SANA AB